Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Fortinet Inc (FTNT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Fortinet Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.75 (market cap $4.49B), while Fortinet Inc trades at $157.05 (market cap $116.25B). The key difference: Fortinet Inc is far larger — about 25.9× ACADIA Pharmaceuticals Inc.'s market cap, and Fortinet Inc is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | FTNT | |
|---|---|---|
Market Cap | $4.49B | $116.25B |
Sector | Health | Technology |
52-Week High | $28.06 | $162.35 |
52-Week Low | $20.06 | $74.39 |
Enterprise Value | $3.69B | $113.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Fortinet (FTNT) trades at $158.67, up 1.55% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with revenue growing to $6.80B in 2025 and net income of $1.85B, though valuation multiples like P/E of 62.93 appear elevated. Recent earnings have consistently beaten expectations, and the company maintains robust profitability with a gross margin of 80.3%. News highlights include AI-driven security growth and upcoming Q2 2026 results announcement on July 29, 2026.
The outlook remains positive due to strong execution and cybersecurity demand, but high valuation and competitive pressures pose risks. Analyst consensus is mixed with a $115.53 price target below current levels, suggesting caution despite bullish technicals. Key risks include execution missteps and market volatility, while institutional sentiment leans neutral with 47.06% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →
